|
 The antibiotic, gepotidacin, is the first of a new class of drugs
and is expected to treat two common bacterial infections, which have
been identified as antibiotic resistant threats by U.S. health
regulators.
Health officials across the world have called for the development of
newer versions of antibiotics as the growing problem of antibiotic
resistance renders some of the most commonly prescribed treatments
ineffective.
GSK's antibiotic will be compared to a combination of ceftriaxone
and azithromycin in about 600 patients with urogential gonorrhoea,
and against nitrofurantoin in nearly 1,200 women with urinary tract
infections. (https://bit.ly/32RNPKN)
[to top of second column] |
Gepotidacin works by selectively interacting with two bacterial
enzymes that aid in bacterial replication, making its mechanism of
action different from other approved antibiotics, the company said.
GSK expects to announce initial results from the study by the end of
2021.
(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shinjini
Ganguli)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
